Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
WALTHAM, Mass., April 25, 2017 -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences. The two conferences are:
- The Leerink Boston Biopharma Bus Tour on Wednesday, May 10, 2017. Lonnie Moulder, CEO, Mary Lynne Hedley, Ph.D., President and COO, and Tim Pearson, EVP and CFO of TESARO, will present at 1:00 PM ET and will answer questions from investors.
- The Bank of America Merrill Lynch 2017 Healthcare Conference at the Loews Hotel in Las Vegas, Nevada on Wednesday, May 17, 2017. Tim Pearson will participate in an analyst-led moderated Q&A at 3:00 PM PT and in meetings with investors.
A live webcast of the presentation at the Bank of America conference will be available by visiting the Investors section of the TESARO website at www.tesarobio.com. An archived replay of this webcast will be available on the Company’s website for 14 days following the conferences.
About TESARO
TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. For more information, visit www.tesarobio.com, and follow us on Twitter and LinkedIn.
For additional information, please contact: Jennifer Davis 1.781.325.1116 [email protected]
